Related Experiment Videos
Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas
Henry F Frierson1, Christopher A Moskaluk, Steven M Powell
1Department of Pathology, University of Virginia Health System, Charlottesville 22908, USA.
Human Pathology
|June 27, 2003
Summary
Mesothelin (MSLN) gene and protein expression was profiled across 150 carcinomas. High expression was found in ovarian and pancreatic cancers, with lower levels in lung, gastric, and colorectal cancers, informing potential therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Mesothelin (MSLN) is a glycoprotein implicated in various cancers.
- Its expression patterns in a wide range of common carcinomas require comprehensive exploration.
Purpose of the Study:
- To comprehensively profile the gene (MSLN) and protein expression of mesothelin in a large series of human carcinomas.
- To identify potential roles of mesothelin as a biomarker or therapeutic target.
Main Methods:
- Utilized oligonucleotide microarrays to assess MSLN gene expression in 150 carcinomas.
- Employed tissue microarrays for mesothelin protein immunodetection in 621 carcinomas.
- Analyzed expression across multiple anatomic sites.
Main Results:
- Highest MSLN expression observed in ovarian (serous) and pancreatic adenocarcinomas.
- Measurable expression also detected in pulmonary, gastric/esophageal, and colorectal adenocarcinomas.
- Low or absent expression noted in prostate, bladder, liver, kidney, and thyroid carcinomas.
Conclusions:
- Mesothelin exhibits differential expression across various cancer types.
- Findings support mesothelin's potential as a serum tumor marker or immunotoxin therapy target.
- Good concordance was observed between gene and protein expression profiling methods.